Lp(a) Lipoprotein(a): The Genetic Heart Risk Factor Nobody Tests For

Imagine a risk factor for heart attack and stroke that has a stronger impact than high cholesterol. Around one in four Europeans has elevated levels (Kamstrup et al., 2009). It is almost entirely determined by genetics, and lifestyle changes have little effect on it (Clarke et al., 2009). And over 90% of doctors in Germany do not routinely test for it.

This risk factor exists. It is called lipoprotein(a), or Lp(a).

You probably don’t know your Lp(a) level. It was likely missing from your last blood test at your general practitioner or cardiologist. This diagnostic gap is one of the most serious issues in modern preventive medicine.

At YEARS in Berlin, measuring Lp(a) is part of the standard cardiovascular assessment. This article explains why, and why you should know your value.

What is Lipoprotein(a)? A definition for non-physicians

Lipoprotein(a) is a lipid particle in the blood, similar to the well-known LDL cholesterol. The difference lies in its structure: an Lp(a) particle consists of an LDL-like core with an additional protein called apolipoprotein(a) attached (Kronenberg et al., 1992).

Think of it as a particularly sticky cholesterol package. This stickiness creates three distinct risks:

Atherogenic

The particle promotes plaque formation in arterial walls and accelerates atherosclerosis (Erqou et al., 2009).

Prothrombotic

It interferes with the body’s ability to break down blood clots, increasing the risk of thrombosis—the most common immediate cause of heart attacks and strokes (Kamstrup et al., 2009).

Proinflammatory

It carries oxidized phospholipids that increase inflammation in vessel walls and destabilize existing plaques (Nordestgaard et al., 2010).

An elevated Lp(a) level therefore stresses the cardiovascular system through three different mechanisms simultaneously.

Lp(a) vs. LDL

LDL measures the amount of cholesterol carried within LDL particles, not their number or inherent risk. You can have completely normal LDL levels and still have an Lp(a) level of 180 mg/dL—a level associated with a substantially increased lifetime risk of heart attacks (Nordestgaard et al., 2010). Standard screening would completely miss this.

The genetic component

Your Lp(a) level is about 90% genetically determined, mainly by variations in the LPA gene (Clarke et al., 2009). Unlike LDL, Lp(a) is largely unaffected by diet, exercise, or statins. Levels remain relatively stable throughout life (Nordestgaard et al., 2010).

This means: someone who never smoked, exercises daily, maintains a BMI of 22, and follows a Mediterranean diet can still have an Lp(a) level of 120 mg/dL and be completely unaware of it. That is why a single test is sufficient—and why it is missing from millions of medical records.

How common is elevated lipoprotein(a)?

Around 20–25% of the European population has Lp(a) levels that significantly increase cardiovascular risk (Kamstrup et al., 2009). Potentially one in four adults in Germany carries this risk without knowing it.

Since the test is rarely ordered, most affected individuals remain undiagnosed. Their genetic predisposition is not documented anywhere.

Heart attack, stroke, aortic stenosis: the Lp(a) risk

Coronary heart disease

Individuals in the highest third of the Lp(a) distribution have nearly double the risk of coronary heart disease compared to those in the lowest third (Erqou et al., 2009). The Copenhagen City Heart Study showed that extremely high Lp(a) levels can triple the risk of heart attacks (Nordestgaard et al., 2010). These are not minor statistical effects.

Stroke

High Lp(a) levels increase the risk of ischemic stroke by approximately 30–50% (Erqou et al., 2009). The mechanism is more direct than with LDL: Lp(a) actively prevents the breakdown of blood clots.

Aortic valve disease

Lp(a) does not only accumulate in coronary arteries but also directly in the aortic valve. Research published in the New England Journal of Medicine demonstrated that genetically elevated Lp(a) significantly increases the lifetime risk of severe aortic stenosis—a calcification and narrowing of the heart’s main valve (Thanassoulis et al., 2013). A 62-year-old with an Lp(a) of 150 mg/dL and no prior clinical findings may carry this risk silently.

Why is Lp(a) not measured routinely?

The reasons are historical, economic, and structural:

Focus on LDL and statins

For decades, research and the pharmaceutical industry focused on lowering LDL. Statins became blockbuster drugs because they effectively reduce LDL. They have little impact on Lp(a), and in some cases may even slightly increase it (Watts et al., 2015).

Therapeutic nihilism

Many physicians long held the view: why measure something that cannot be treated? Without approved Lp(a)-specific therapies, the test was considered of limited clinical use. This perspective is now changing as new treatments are approaching approval.

Lack of guideline implementation

European cardiology societies have recommended since 2019 that every adult should have their Lp(a) measured at least once (Catapano et al., 2019). In practice, many patients never receive this test.

Reimbursement

Statutory health insurance in Germany typically covers Lp(a) testing only for specific indications, not as general preventive screening. As an out-of-pocket test, it usually costs between €20 and €40.

Reference values and risk thresholds

Lp(a) is measured in milligrams per deciliter (mg/dL) or nanomoles per liter (nmol/L). Due to differences in particle size, conversion is imprecise; roughly, 1 mg/dL corresponds to about 2.5 nmol/L (Nordestgaard et al., 2010).

European guidelines define the following thresholds (Catapano et al., 2019):

• Low risk: below 30 mg/dL (below 75 nmol/L)
• Elevated risk: 30–50 mg/dL (75–125 nmol/L)
• High risk: above 50 mg/dL (above 125 nmol/L)
• Very high risk: above 100 mg/dL (above 250 nmol/L)

Levels above 180 mg/dL are associated with a lifetime cardiovascular risk comparable to heterozygous familial hypercholesterolemia (Nordestgaard et al., 2010).

Levels are similarly distributed in men and women and change little over time. Individuals of African ancestry tend to have higher average Lp(a) levels than European populations (Kamstrup et al., 2009).

What can you do about high lipoprotein(a)?

What does not work

Diet, weight loss, and exercise have virtually no effect on Lp(a) levels. Statins do not lower Lp(a) and may even slightly increase it in some patients (Watts et al., 2015). High-dose niacin can reduce Lp(a) by about 20–30%, but is no longer recommended due to significant side effects and lack of evidence for reducing cardiovascular events (Nordestgaard et al., 2010).

New therapies on the horizon

Antisense oligonucleotides and siRNAs block Lp(a) production in the liver at a genetic level. Clinical trials with pelacarsen show reductions of over 80% (Tsimikas et al., 2020). These therapies are not yet approved, but several phase 3 programs are ongoing. For patients with very high Lp(a), this is one of the most relevant developments in cardiology in recent years.

The strategy that works now

If you carry a non-modifiable risk factor, you need to control all other risk factors more aggressively. For individuals with high Lp(a), this means:

Very low LDL targets below 70 mg/dL, and below 55 mg/dL in very high-risk cases. A systolic blood pressure below 130 mmHg. Low inflammatory markers, assessed via hs-CRP. No insulin resistance, measured via the HOMA index. No smoking, consistent treatment of sleep apnea, and control of body weight.

A 45-year-old with an Lp(a) of 90 mg/dL and LDL of 140 mg/dL has a significantly worse risk profile than someone with the same LDL but Lp(a) below 20 mg/dL. This leads to different targets, different treatment thresholds, and potentially earlier initiation of lipid-lowering therapy.

Who should get tested?

European guidelines recommend a one-time test for every adult (Catapano et al., 2019). It is particularly important if:

• There is a family history of heart attacks or strokes before age 55 in men or 65 in women
• You have known coronary heart disease, especially with normal or only mildly elevated cholesterol levels
• You have familial hypercholesterolemia
• You experience recurrent cardiovascular events despite optimal therapy

If your level is elevated, siblings and children should also be informed, as the inheritance probability is about 50% (Clarke et al., 2009).

Lp(a) in the context of YEARS diagnostics

Individual biomarkers have limited value. An Lp(a) level of 80 mg/dL means something different depending on LDL, blood pressure, and inflammatory status.

In the statutory check-up at age 35, Lp(a) is systematically missing. In the YEARS Core® program, it is part of an 87-biomarker panel alongside ApoB and hs-CRP. ApoB measures the total number of atherogenic particles more precisely than LDL alone. High Lp(a) combined with high ApoB and elevated hs-CRP signals a qualitatively different risk than any marker alone.

Lp(a) and genomics

The YEARS Ultimate® program combines blood measurement with full genome sequencing. This allows not only determination of Lp(a) levels but also identification of the specific LPA gene variants responsible. This level of detail becomes relevant as soon as the first approved Lp(a) therapies are available and treatment decisions can be personalized genetically.

Frequently asked questions about lipoprotein(a)

Is Lp(a) hereditary?

About 90% (Clarke et al., 2009). If your level is elevated, each child and sibling has a 50% probability of being affected.

Can I lower Lp(a) through exercise or a keto diet?

No. Lifestyle changes have no meaningful impact on Lp(a) levels.

Does vitamin D or niacin affect Lp(a)?

Niacin can reduce Lp(a) by about 20%, but is no longer recommended due to side effects and lack of evidence for cardiovascular benefit (Nordestgaard et al., 2010). There is no proven effect of vitamin D on Lp(a).

My Lp(a) is 110 mg/dL. What now?

110 mg/dL falls into the very high-risk category. This means: discuss specific LDL, blood pressure, and inflammatory targets with a physician. Use stress testing or coronary artery calcium (CAC) scoring to assess whether subclinical disease is already present. And monitor developments around pelacarsen and similar therapies. The value is information—not a diagnosis or a verdict.

Get tested. Know your number.

There is a significant gap between what cardiology knows about Lp(a) and what is measured in everyday practice. The evidence is clear, the test costs €20–40, and the value remains stable over a lifetime.

If you want to proactively manage your cardiovascular health, you need this number. It changes targets, treatment thresholds, and prevention strategies—sometimes substantially.

At YEARS, Lp(a) is part of the standard. If you want to go beyond the statutory check-up, this is one of the most meaningful first steps

Schedule a consultation to learn how comprehensive diagnostics including Lp(a) can change your prevention strategy.

This article is for general information only and does not replace medical advice. The interpretation of laboratory values such as Lp(a) must always be done in the context of a full clinical assessment by a physician.

References

Catapano, A. L., Graham, I., De Backer, G., et al. (2019). 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455

Clarke, R., Peden, J. F., Hopewell, J. C., et al. (2009). Genetic variants associated with Lp(a) lipoprotein level and risk of coronary disease. Nature Genetics, 41(11), 1162–1167. https://doi.org/10.1038/ng.486

Erqou, S., Kaptoge, S., Perry, P. L., et al. (2009). Lipoprotein(a) concentration and the risk of coronary heart disease. JAMA, 302(4), 412–423. https://doi.org/10.1001/jama.2009.1063

Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2009). Genetic evidence that lipoprotein(a) causes cardiovascular disease. Circulation, 120(3), 205–214. https://doi.org/10.1161/CIRCULATIONAHA.109.870629

Kronenberg, F., Utermann, G., & Dieplinger, H. (1992). Lipoprotein(a) in clinical practice. European Journal of Clinical Investigation, 22(8), 519–535.

Nordestgaard, B. G., Chapman, M. J., Ray, K., et al. (2010). Lipoprotein(a) as a cardiovascular risk factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(7), e11–e17. https://doi.org/10.1161/ATVBAHA.110.207464

Thanassoulis, G., Campbell, C. Y., Owens, D. S., et al. (2013). Genetic associations with valvular calcification and aortic stenosis. New England Journal of Medicine, 368(6), 503–512. https://doi.org/10.1056/NEJMoa1109034

Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., et al. (2020). Lipoprotein(a) reduction in persons with cardiovascular disease. New England Journal of Medicine, 382(3), 244–255. https://doi.org/10.1056/NEJMoa1905239

Watts, G. F., Ooi, E. M., & Chan, D. C. (2015). Demystifying the management of lipoprotein(a). Circulation, 132(13), 1171–1173. https://doi.org/10.1161/CIRCULATIONAHA.115.018266